Axon Therapies is advancing Splanchnic Ablation for Volume Management (SAVM), a minimally invasive procedure that targets sympathetic nervous system overactivity, a root physiological driver of heart failure. Its Satera™ Ablation System delivers the therapy without leaving an implant, aiming to slow disease progression and improve patient quality of life. The company is entering its next phase of clinical development, funding two double-blinded randomized feasibility studies for both preserved (HFpEF) and reduced (HFrEF) ejection-fraction heart failure populations. Axon plans to progress to pivotal trials following successful feasibility outcomes and views Europe as a strategic expansion market, establishing a new headquarters in the UK to accelerate trial execution there. Leadership was strengthened with the appointment of co-founder Zoar Engelman, PhD, as Chief Executive Officer. The recent $32 million Series A financing brings total capital raised to at least that amount, providing runway for these clinical objectives. No revenue or patient-use metrics were disclosed in the article.

Total raised

$32M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2025